Data as of Q4 2025 (Dec 31, 2025)

SINOVAC BIOTECH LTD

(SVA)

Financial Statements · SEC EDGAR XBRL

Revenue
$361.4M
-23.1%
EPS
$1.27
+768.4%
Gross Margin
61.1%
Op. Income
-$505.5M
+29.2%
FCF
-$152.9M
-772.4%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Cost of Revenues
Gross Profit
Operating Expenses & Income
Selling General & Admin
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
$361.4M
$470.2M
$1.47B
$19.37B
$510.6M
$361.4M
$470.2M
$1.47B
$19.37B
$510.6M
$140.7M
$146.9M
$658.2M
$988.9M
$67.2M
$220.7M
$323.3M
$815.2M
$18.38B
$443.4M
$420.9M
$598.3M
$836.1M
$602.1M
$176.5M
$270.7M
$350.2M
$478.7M
$152.7M
$48.8M
$726.2M
$1.04B
$1.32B
$758.1M
$227.8M
-$505.5M
-$714.0M
-$509.0M
$17.62B
$215.6M
$527.6M
$558.8M
$296.6M
-$153.0M
$496K
$42.8M
-$84.5M
-$48.5M
$17.57B
$216.6M
$2.2M
$36.4M
$11.5M
$3.45B
$31.4M
-
-$13.5M
$14.5M
$8.12B
$110.4M
$1.27
$-0.19
$0.20
$113.54
$1.06
$1.27
$-0.19
$0.20
$113.44
$0.97
71.9M
71.9M
71.8M
71.6M
113.7M